Focused On-demand Library for C-X-C motif chemokine 14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95715

UPID:

CXL14_HUMAN

Alternative names:

Chemokine BRAK; MIP-2G; Small-inducible cytokine B14

Alternative UPACC:

O95715; B3KQU8; Q6UW97; Q86U69; Q9BTR1; Q9NS21

Background:

C-X-C motif chemokine 14, also known as Chemokine BRAK, MIP-2G, and Small-inducible cytokine B14, plays a crucial role in the immune system. It acts as a potent chemoattractant for neutrophils and to a lesser extent for dendritic cells, but does not attract T-cells, B-cells, monocytes, natural killer cells, or granulocytes. Furthermore, it does not inhibit the proliferation of myeloid progenitors.

Therapeutic significance:

Understanding the role of C-X-C motif chemokine 14 could open doors to potential therapeutic strategies. Its specific function as a chemoattractant highlights its importance in immune response regulation, suggesting its potential in modulating immune-related conditions.